Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -847.24% is 62% below its 2-year average of -523.24%, around the middle of its 2-year range (-1132.37%–-264.74%).
188.79% below its 12-month average of -293.38%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -264.74%.
EBITDA MARGIN
-847.24%
EBITDA MARGIN AVG TTM
-293.38%
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-188.79%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Prelude Therapeutics Incorporated
Market Cap
$211.79M
EBITDA Margin
-847.24%
TTM Avg
-293.38%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$211.33M
EBITDA Margin
43.70%
TTM Avg
-4.00%
3Y Avg
-127.66%
5Y Avg
-437.76%
Market Cap
$214.30M
EBITDA Margin
-533986.11%
TTM Avg
-544963.54%
3Y Avg
-316138.98%
5Y Avg
-211520.31%
Market Cap
$214.64M
EBITDA Margin
12.17%
TTM Avg
10.71%
3Y Avg
-1.62%
5Y Avg
-12.53%
Market Cap
$208.47M
EBITDA Margin
-611.99%
TTM Avg
-293.95%
3Y Avg
-196.05%
5Y Avg
-196.05%
Market Cap
$216.82M
EBITDA Margin
66.70%
TTM Avg
45.54%
3Y Avg
40.95%
5Y Avg
43.86%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Prelude Therapeutics Incorporated (PRLD) | $211.79M | -847.24% | -293.38% | N/A | N/A |
| Compugen Ltd. (CGEN)vs › | $211.33M | 43.70% | -4.00% | -127.66% | -437.76% |
| Lyell Immunopharma, Inc. (LYEL)vs › | $214.30M | -533986.11% | -544963.54% | -316138.98% | -211520.31% |
| Niagen Bioscience Inc (NAGE)vs › | $214.64M | 12.17% | 10.71% | -1.62% | -12.53% |
| Electra Therapeutics Inc. (ETRA)vs › | $208.65M | N/A | N/A | N/A | N/A |
| Pro-Dex, Inc. (PDEX)vs › | $208.63M | 18.55% | 18.23% | 16.57% | 15.69% |
| Entrada Therapeutics, Inc. (TRDA)vs › | $208.47M | -611.99% | -293.95% | -196.05% | -196.05% |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $216.82M | 66.70% | 45.54% | 40.95% | 43.86% |
| Sionna Therapeutics, Inc. (SION)vs › | $205.81M | N/A | N/A | N/A | N/A |
| Alector, Inc. (ALEC)vs › | $205.40M | -646.93% | -391.16% | -256.59% | -321.84% |
Gross Margin
85.9%
EBITDA Margin
-847.2%
Operating Margin
-861.3%
Net Margin
-269.8%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -264.74% |
| 2026-03-31 | -301.00% |
| 2025-12-31 | -300.18% |
| 2025-09-30 | -307.58% |
| 2024-12-31 | -833.55% |
| 2024-09-30 | -1132.37% |
